Welcome to ACCESS DMD™, an expanded access program that is now available for children, adolescents, and adults in the U.S. diagnosed with Duchenne muscular dystrophy (DMD).

The intent of an expanded access program is to provide patients with access to investigational medication for serious diseases or conditions where there is no comparable or satisfactory alternative therapy available. The ACCESS DMD™ program will enable participating physicians to obtain and provide deflazacort*, an investigational medication for eligible U.S. patients diagnosed with DMD, while it is under development.

While participating in ACCESS DMD™, deflazacort* will be provided to eligible U.S. patients at no cost, and it will be sent directly to patients or their caregivers. To learn more about ACCESS DMD™, please follow one of the links below:

Please click below if you are a:

*Deflazacort is an investigational medication that has not been approved by the Food and Drug Administration (FDA) and is therefore not proven to be safe and effective.

ACCESSDMD is a trademark of Marathon Pharmaceuticals, LLC